Dr. Reddy's Launches Toripalimab for Advanced Nasopharyngeal Cancer Treatment

Dr Reddy's Laboratories announced the introduction of Toripalimab in India for treating recurrent or metastatic nasopharyngeal carcinoma. Nasopharyngeal carcinoma (NPC) is an uncommon, fast-growing type of head and neck cancer that starts in the nasopharynx, the top section of the throat.

In a regulatory filing, Dr. Reddy's Laboratories announced the release of a new biological entity (NBE) called Toripalimab. The drug is the sole immuno-oncology medication endorsed by multiple regulatory bodies globally like USFDA, EMA, MHRA, for treating adults with RM-NPC.

Dr Reddy's lab plans to launch the medication in India with the brand name Zytorvi.

"As the next generation PD-1 inhibitor, Toripalimab has demonstrated superior outcomes for RM-NPC versus standard of care, thereby meeting a significant unmet need for patients with NPC in India," Dr Reddy's CEO Branded Markets (India and Emerging Markets) MV Ramana said.

The leading pharmaceutical firm has prioritized oncology as a key therapy area, successfully introducing Toripalimab in India at the same time as its launch in the US.

"We will continue to work hard to serve our patients and stakeholders to remain their partner of choice, and progress towards our goal of serving over 1.5 billion patients by 2030," Ramana said.